360 related articles for article (PubMed ID: 29282336)
21. Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer's disease.
Pereira JB; Westman E; Hansson O;
Neurobiol Aging; 2017 Oct; 58():14-29. PubMed ID: 28692877
[TBL] [Abstract][Full Text] [Related]
22. Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detection.
Peterson J; Gisslen M; Zetterberg H; Fuchs D; Shacklett BL; Hagberg L; Yiannoutsos CT; Spudich SS; Price RW
PLoS One; 2014; 9(12):e116081. PubMed ID: 25541953
[TBL] [Abstract][Full Text] [Related]
23. Comparison between plasma and cerebrospinal fluid biomarkers for the early diagnosis and association with survival in prion disease.
Abu-Rumeileh S; Baiardi S; Ladogana A; Zenesini C; Bartoletti-Stella A; Poleggi A; Mammana A; Polischi B; Pocchiari M; Capellari S; Parchi P
J Neurol Neurosurg Psychiatry; 2020 Nov; 91(11):1181-1188. PubMed ID: 32928934
[TBL] [Abstract][Full Text] [Related]
24. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial.
Boxer AL; Lang AE; Grossman M; Knopman DS; Miller BL; Schneider LS; Doody RS; Lees A; Golbe LI; Williams DR; Corvol JC; Ludolph A; Burn D; Lorenzl S; Litvan I; Roberson ED; Höglinger GU; Koestler M; Jack CR; Van Deerlin V; Randolph C; Lobach IV; Heuer HW; Gozes I; Parker L; Whitaker S; Hirman J; Stewart AJ; Gold M; Morimoto BH;
Lancet Neurol; 2014 Jul; 13(7):676-85. PubMed ID: 24873720
[TBL] [Abstract][Full Text] [Related]
25. Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
Fortea J; Carmona-Iragui M; Benejam B; Fernández S; Videla L; Barroeta I; Alcolea D; Pegueroles J; Muñoz L; Belbin O; de Leon MJ; Maceski AM; Hirtz C; Clarimón J; Videla S; Delaby C; Lehmann S; Blesa R; Lleó A
Lancet Neurol; 2018 Oct; 17(10):860-869. PubMed ID: 30172624
[TBL] [Abstract][Full Text] [Related]
26. Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study.
Lleó A; Alcolea D; Martínez-Lage P; Scheltens P; Parnetti L; Poirier J; Simonsen AH; Verbeek MM; Rosa-Neto P; Slot RER; Tainta M; Izaguirre A; Reijs BLR; Farotti L; Tsolaki M; Vandenbergue R; Freund-Levi Y; Verhey FRJ; Clarimón J; Fortea J; Frolich L; Santana I; Molinuevo JL; Lehmann S; Visser PJ; Teunissen CE; Zetterberg H; Blennow K
Alzheimers Dement; 2019 Jun; 15(6):742-753. PubMed ID: 30967340
[TBL] [Abstract][Full Text] [Related]
27. Poor sleep is associated with CSF biomarkers of amyloid pathology in cognitively normal adults.
Sprecher KE; Koscik RL; Carlsson CM; Zetterberg H; Blennow K; Okonkwo OC; Sager MA; Asthana S; Johnson SC; Benca RM; Bendlin BB
Neurology; 2017 Aug; 89(5):445-453. PubMed ID: 28679595
[TBL] [Abstract][Full Text] [Related]
28. Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study.
de Wolf F; Ghanbari M; Licher S; McRae-McKee K; Gras L; Weverling GJ; Wermeling P; Sedaghat S; Ikram MK; Waziry R; Koudstaal W; Klap J; Kostense S; Hofman A; Anderson R; Goudsmit J; Ikram MA
Brain; 2020 Apr; 143(4):1220-1232. PubMed ID: 32206776
[TBL] [Abstract][Full Text] [Related]
29. Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia.
Landqvist Waldö M; Frizell Santillo A; Passant U; Zetterberg H; Rosengren L; Nilsson C; Englund E
BMC Neurol; 2013 May; 13():54. PubMed ID: 23718879
[TBL] [Abstract][Full Text] [Related]
30. Cathepsin S increases tau oligomer formation through limited cleavage, but only IL-6, not cathespin S serum levels correlate with disease severity in the neurodegenerative tauopathy progressive supranuclear palsy.
Nübling G; Schuberth M; Feldmer K; Giese A; Holdt LM; Teupser D; Lorenzl S
Exp Brain Res; 2017 Aug; 235(8):2407-2412. PubMed ID: 28493068
[TBL] [Abstract][Full Text] [Related]
31. Non-neurological surgery and cerebrospinal fluid biomarkers for neuronal and astroglial integrity.
Anckarsäter R; Anckarsäter H; Bromander S; Blennow K; Wass C; Zetterberg H
J Neural Transm (Vienna); 2014 Jun; 121(6):649-53. PubMed ID: 24420082
[TBL] [Abstract][Full Text] [Related]
32. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration.
Scherling CS; Hall T; Berisha F; Klepac K; Karydas A; Coppola G; Kramer JH; Rabinovici G; Ahlijanian M; Miller BL; Seeley W; Grinberg LT; Rosen H; Meredith J; Boxer AL
Ann Neurol; 2014 Jan; 75(1):116-26. PubMed ID: 24242746
[TBL] [Abstract][Full Text] [Related]
33. Associations of longitudinal plasma p-tau181 and NfL with tau-PET, Aβ-PET and cognition.
Rauchmann BS; Schneider-Axmann T; Perneczky R;
J Neurol Neurosurg Psychiatry; 2021 Dec; 92(12):1289-1295. PubMed ID: 34187867
[TBL] [Abstract][Full Text] [Related]
34. CSF neurofilament light concentration is increased in presymptomatic
Rostgaard N; Roos P; Portelius E; Blennow K; Zetterberg H; Simonsen AH; Nielsen JE
Neurology; 2018 Jan; 90(2):e157-e163. PubMed ID: 29237796
[TBL] [Abstract][Full Text] [Related]
35. Neurofilament Light Chain Levels in Frontotemporal Dementia and Progressive Supranuclear Palsy: A Systematic Review.
Bendstrup N; Hejl AM; Salvesen L
J Alzheimers Dis; 2022; 87(1):131-140. PubMed ID: 35275542
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer's disease.
Lista S; Toschi N; Baldacci F; Zetterberg H; Blennow K; Kilimann I; Teipel SJ; Cavedo E; Dos Santos AM; Epelbaum S; Lamari F; Dubois B; Floris R; Garaci F; Hampel H;
Neurochem Int; 2017 Sep; 108():355-360. PubMed ID: 28527630
[TBL] [Abstract][Full Text] [Related]
37. Subtle Differences in Cognition in 70-Year-Olds with Elevated Cerebrospinal Fluid Neurofilament Light and Neurogranin: A H70 Cross-Sectional Study.
Rådestig MA; Skoog J; Zetterberg H; Skillbäck T; Zettergren A; Sterner TR; Fässberg MM; Sacuiu S; Waern M; Wetterberg H; Blennow K; Skoog I; Kern S
J Alzheimers Dis; 2023; 91(1):291-303. PubMed ID: 36617786
[TBL] [Abstract][Full Text] [Related]
38. Tracking and predicting disease progression in progressive supranuclear palsy: CSF and blood biomarkers.
Jabbari E; Zetterberg H; Morris HR
J Neurol Neurosurg Psychiatry; 2017 Oct; 88(10):883-888. PubMed ID: 28600442
[TBL] [Abstract][Full Text] [Related]
39. Relationship between cerebrospinal fluid neurodegeneration biomarkers and temporal brain atrophy in cognitively healthy older adults.
Vidal-Piñeiro D; Sørensen Ø; Blennow K; Capogna E; Halaas NB; Idland AV; Mowinckel AM; Pereira JB; Watne LO; Zetterberg H; Walhovd KB; Fjell AM;
Neurobiol Aging; 2022 Aug; 116():80-91. PubMed ID: 35584575
[TBL] [Abstract][Full Text] [Related]
40. CSF biomarkers β-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes.
Constantinides VC; Paraskevas GP; Emmanouilidou E; Petropoulou O; Bougea A; Vekrellis K; Evdokimidis I; Stamboulis E; Kapaki E
J Neurol Sci; 2017 Nov; 382():91-95. PubMed ID: 29111028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
